24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
SUNITCAP 12.5MG is an Capsules medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | SUNITCAP 12.5MG |
|---|---|
| Composition | Sunitinib Malate Capsules 12.5mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsules |
| Packaging | Btl (28 tab) |
| Country of Origin | India |
SUNITCAP 12.5MG (Sunitinib Malate Capsules 12.5mg) is a widely used Capsules medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
SUNITCAP 12.5 MG (Sunitinib Malate Capsules 12.5 mg) is a prescription targeted anticancer medicine containing Sunitinib Malate 12.5 mg, a potent Tyrosine Kinase Inhibitor (TKI) used in the treatment of various advanced and metastatic cancers. Sunitinib works by blocking specific proteins responsible for cancer cell growth, tumor progression, and the formation of blood vessels that supply nutrients to tumors.
Cancer cells rely on multiple signaling pathways to grow and spread throughout the body. Sunitinib targets these pathways by inhibiting several receptor tyrosine kinases, helping to slow tumor growth and reduce the development of new blood vessels required for cancer progression. This targeted approach makes it an important option in modern oncology treatment.
Unlike conventional chemotherapy, which may affect both healthy and cancerous rapidly dividing cells, Sunitinib specifically targets molecular pathways involved in tumor development. This precision-based mechanism supports effective long-term disease management in eligible patients.
SUNITCAP 12.5 MG is commonly prescribed for:
The 12.5 mg strength is frequently used for dose adjustments, maintenance therapy, combination dosing schedules, and patients requiring lower doses based on individual treatment response and tolerability.
Manufactured according to stringent pharmaceutical quality standards, SUNITCAP 12.5 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients receiving Sunitinib therapy require regular monitoring, including blood pressure assessments, complete blood counts, liver function testing, thyroid evaluations, and clinical examinations to ensure optimal treatment outcomes.
Due to its proven effectiveness in targeted cancer therapy, SUNITCAP 12.5 MG remains an important medicine in contemporary oncology care.
SUNITCAP 12.5 MG (Sunitinib Malate Capsules 12.5 mg) is primarily used in the treatment and management of specific advanced cancers.
The medicine is widely prescribed for advanced and metastatic kidney cancer.
Sunitinib may be used in patients whose disease has progressed despite previous treatment.
The medicine helps manage advanced neuroendocrine tumors originating in the pancreas.
Doctors may recommend Sunitinib to help control cancer progression and tumor growth.
The medicine forms part of personalized cancer treatment strategies.
Sunitinib supports disease stabilization and prolonged treatment response.
The 12.5 mg strength allows flexible dosing according to patient-specific requirements.
Sunitinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs).
SUNITCAP works by:
This targeted mechanism helps control cancer growth and spread more effectively.
Like all medicines, SUNITCAP 12.5 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Weakness and tiredness are frequently reported during treatment.
Elevated blood pressure may occur and should be monitored regularly.
Digestive disturbances may develop during therapy.
Some patients may experience nausea.
Reduced appetite may affect nutritional intake.
Inflammation or ulcers inside the mouth may occur.
Changes in skin color or pigmentation may develop.
Redness, swelling, and discomfort of the hands and feet may occur.
The medicine may affect thyroid hormone levels.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of SUNITCAP 12.5 MG (Sunitinib Malate Capsules 12.5 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the cancer being treated.
Cancer severity and progression influence therapy planning.
Liver, kidney, thyroid, and heart health may affect dosage decisions.
Doctors may adjust treatment according to effectiveness and tolerability.
Potential drug interactions may require dosage modifications.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, supplements, vitamins, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is used for the treatment of advanced kidney cancer, gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (pNET).
Sunitinib Malate is a targeted anticancer medicine that blocks proteins involved in cancer growth and blood vessel formation.
No. It is a targeted therapy known as a tyrosine kinase inhibitor and works differently from traditional chemotherapy.
The 12.5 mg strength is commonly used for dose adjustments, maintenance therapy, and individualized treatment schedules.
Yes. High blood pressure is a common side effect and requires regular monitoring.
Yes. Changes in thyroid hormone levels may occur and should be monitored periodically.
Yes. Blood pressure checks, blood tests, thyroid assessments, and clinical evaluations are important throughout therapy.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and targeted cancer treatment.